What is the risk of Stevens-Johnson syndrome (SJS) with oxcarbazepine (Trileptal) versus lamotrigine (Lamictal)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Risk of Stevens-Johnson Syndrome: Lamotrigine vs Oxcarbazepine

Lamotrigine (Lamictal) carries a significantly higher risk of SJS than oxcarbazepine (Trileptal), with lamotrigine showing approximately 2.6 times greater absolute risk based on the most recent population-based data.

Quantified Risk Comparison

The most robust evidence comes from a 2026 Danish nationwide cohort study tracking nearly 1.4 million antiseizure medication initiations 1:

  • Lamotrigine: 29.31 cases per 100,000 initiators (95% CI: 21.46-39.09)
  • Oxcarbazepine: 11.25 cases per 100,000 initiators (95% CI: 3.65-26.25)
  • Background population risk: 0.17 per 100,000 individuals

This translates to lamotrigine increasing SJS/TEN risk approximately 172-fold above background, while oxcarbazepine increases risk approximately 66-fold above background.

Critical Timing Considerations

Both medications pose highest risk within the first 2-4 weeks of initiation 1, 2. The Danish study showed most cases occurred within the initial weeks, with the FDA label for Trileptal reporting a median onset of 19 days 3. This early window is when vigilance must be most intense.

Clinical Context from Guidelines

Both lamotrigine and oxcarbazepine are explicitly listed among the most common drugs causing SJS/TEN in the 2016 UK guidelines 4. However, the quantitative difference matters significantly for risk stratification and informed consent discussions.

Genetic Risk Modifiers

HLA-B*1502 allele testing should be considered for both drugs in at-risk populations (Han Chinese 2-12%, Thai 8%, Filipino >15%, Korean/Indian 2-6%) 3, 5. The association is:

  • Stronger for oxcarbazepine (structurally similar to carbamazepine, which has the strongest HLA-B*1502 association)
  • Milder but still significant for lamotrigine 5

In HLA-B*1502 positive patients from high-risk populations, oxcarbazepine should be avoided unless benefits clearly outweigh risks 3.

Pediatric Considerations

A pooled analysis of pediatric cases (<15 years) confirmed both carbamazepine and lamotrigine as strongly associated with SJS/TEN 6. While oxcarbazepine data in children is more limited, case reports demonstrate similar clinical patterns with onset typically within 2 weeks 2.

Key Risk Amplifiers

For lamotrigine specifically:

  • Co-administration with valproic acid dramatically increases risk (present in 50% of reported cases) 7
  • Rapid dose titration increases risk
  • Mitochondrial disorders may potentiate risk 8

For oxcarbazepine:

  • 25-30% cross-reactivity in patients with prior carbamazepine hypersensitivity 3
  • HLA-B*1502 positive status in at-risk populations

Clinical Warning Signs Requiring Immediate Action

Discontinue medication immediately if any of these develop:

  • Fever with mucocutaneous lesions
  • Painful skin rash with blistering
  • Conjunctivitis with ocular discharge
  • Oral/mucosal erosions
  • Target-like lesions or epidermal detachment

Mortality risk is 17% at one year for SJS/TEN cases 1, making early recognition life-saving.

Practical Prescribing Algorithm

  1. Pre-prescription: Screen for HLA-B*1502 in genetically at-risk populations before starting either drug
  2. Patient education: Warn about early signs (fever + rash) and instruct to stop medication and seek emergency care immediately
  3. First 4 weeks: Most intensive monitoring period; consider weekly check-ins
  4. Lamotrigine-specific: Avoid co-prescription with valproic acid when possible; use slow titration protocols
  5. Oxcarbazepine-specific: Explicitly ask about prior carbamazepine reactions; avoid if positive history

Bottom Line for Clinical Decision-Making

When choosing between these agents for epilepsy management, lamotrigine carries 2.6 times higher absolute SJS risk than oxcarbazepine based on the highest quality contemporary evidence 1. However, both exceed background population risk by orders of magnitude, making early recognition protocols mandatory regardless of choice. The decision should factor in HLA-B*1502 status in at-risk populations (favoring neither drug if positive), prior carbamazepine exposure (avoiding oxcarbazepine if hypersensitivity occurred), and concomitant valproic acid use (avoiding lamotrigine if possible).

References

Related Questions

For an 18-year-old male who had his lamotrigine dose increased from 25 mg to 50 mg, what are the next best steps to assess the rash for Stevens‑Johnson syndrome and when should referral to the emergency department be recommended?
What is the likelihood of Stevens-Johnson syndrome occurring with lamotrigine in a patient who previously experienced Stevens-Johnson syndrome with terbinafine (Lamisil)?
What are the symptoms of Stevens-Johnson syndrome associated with lamotrigine (Lamictal) and when should medical treatment be sought?
In a patient taking lamotrigine (Lamictal) who develops throat pain a few days after a dose increase without fever, rash, or itching, could this be a side effect of lamotrigine or an early sign of Stevens‑Johnson syndrome?
What non‑lithium, non‑valproate mood‑stabilizing regimen is appropriate for a bipolar patient who cannot use lamotrigine due to Stevens‑Johnson syndrome and is currently taking methylphenidate?
Is sharp pleuritic chest pain indicative of pulmonary embolism?
What is the likely diagnosis for a patient with persistent hypokalemia despite one year of oral potassium chloride therapy?
What is the recommended starting dose of escitalopram (Lexapro) in adults, and how does it differ for patients ≥ 65 years or with hepatic impairment?
What is the optimal duration to discontinue clopidogrel in a 60-year-old patient undergoing transurethral resection of the prostate (TURP)?
Which ADHD medication(s) are effective for treating both attention-deficit/hyperactivity disorder and co‑occurring mood and anxiety symptoms?
In a patient with a history of deep‑vein thrombosis undergoing transurethral resection of the prostate who is taking clopidogrel, how should clopidogrel and anticoagulation be managed perioperatively?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.